PHSI-BRG
PHSI-BRG
Home
Staff
Sarah Al Ashmori
Andy Bryant
Thomas Chadwick
Svetlana Cherlin
Mike Cole
Holly Fisher
Tony Fouweather
Shaun Hiu
Dorcas Kareithi
Ann Breeze Konkoth
Nan Lin
Jingky Lozano-Kuehne
Helen Mossop
Ellen Moss
Aritra Mukherjee
Jérémie Nsengimana
Vicky Ryan
Marzieh Shahmandi
Moha Shojaei
Dawn Teare
James Wason
Faye Williamson
Nina Wilson
Sylvia Zhang
PhD students
Ruqayya Azher
Nicole Cizauskas
Laura Etfer
Niamh Fitzgerald
Raiann Hamshaw
Pela Okorie
Samuel Sarkodie
Lou Whitehead
Methodology research
Overview
Adaptive designs
Master protocols
Transforming IMID trials
Projects
Publications
News
Courses
Adaptive Designs and Multiple Testing Procedures
Leveraging External Information
Precision Medicine Clinical Trials
Contact
Light
Dark
Automatic
Wason
Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: A structured summary of a study protocol for a randomised controlled trial
*Trials* 2021; 22:270
Treatment allocation strategies for umbrella trials in the presence of multiple biomarkers: A comparison of methods
*Pharmaceutical Statistics* 2021; doi:10.1002/pst.2119
Statistical consideration when adding new arms to ongoing clinical trials: The potentials and the caveats
*Trials* 2021; 22:203
Mentalization for Offending Adult Males (MOAM): Study protocol for a randomized controlled trial to evaluate mentalization-based treatment for antisocial personality disorder in male offenders on community probation
*Trials* 2020; 21:1001
PSU4 Value of information for adaptive trials: Proof of concept study in multi-arm multi-stage trials of interventions for the prevention of surgical site infections
*Value in Health* 2020; 23(S2):S738
Ensuring that COVID-19 research is inclusive: Guidance from the NIHR INCLUDE project
*BMJ Open* 2020; 10(11):e043634
Efficient analysis of time-to-event endpoints when the event involves a continuous variable crossing a threshold
*Journal of Statistical Planning and Inference* 2020; 208:119-29
Controlling type I error rates in multi-arm clinical trials: A case for the false discovery rate
*Pharmaceutical Statistics* 2020
Increasing power in the analysis of responder endpoints in rheumatology: a software tutorial
*medRxiv* 2020
Developing and testing high-efficacy patient subgroups within a clinical trial using risk scores
*Statistics in Medicine* 2020; 39(24):3285-3298
«
»
Cite
×